. Author manuscript; available in PMC: 2014 Oct 1.

Published in final edited form as: Obesity (Silver Spring). 2013 Dec 6;22(4):1024–1031. doi: 10.1002/oby.20653

Table 1.

Baseline characteristics of postmenopausal women randomized to placebo, raloxifene, or hormone therapy (HT).

	Treatment Group
	placebo n = 38	raloxifene n =38	HT n =43
Age, yr	56±5	56±4	56±4
Age at menopause, yr	47±6	47±6	47±7
Time since menopause, yr	9.2±8.3	8.5±7.3	9.0±7.9
Hysterectomy, n (%)	13 (34%)	13 (34%)	14 (33%)
Time since last HT use, yr (n)	3.7±5.0 (28)	2.6±3.3 (21)	2.7±4.3 (26)
Duration of previous HT use, yr	4.7±7.9	5.8±7.0	4.5±4.8
VO₂ peak, L/min	1.76±0.25	1.78±0.36	1.69±0.25
Height, cm	164.0±6.2	163.2±8.1	163.2±6.9
Weight, kg	80.8±12.3	81.4±13.2	78.7±12.6
BMI, kg/m²	30.0±4.1	30.6±4.7	29.7±4.5